US2009169628A1PendingUtilityA1

Article and method for focused delivery of therapeutic and/or diagnostic materials

61
Assignee: ARMARK AUTHENTICATION TECHNOLOPriority: Oct 17, 2006Filed: Dec 23, 2008Published: Jul 2, 2009
Est. expiryOct 17, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Peter D. GabrieleMichael S. FlemmensJeffrey H. RobertsonAndrew Hogan
A61K 9/70A61K 9/0009A61K 31/167A61P 25/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.

Claims

exact text as granted — not AI-modified
1 . A microfiber extrudate comprising:
 a bio-compatible polymer matrix forming a body of the microfiber extrudate;   an exogenously excitable material arranged within the body; and   an active load arranged within the body.   
     
     
         2 . The microfiber matrix of  claim 1 , wherein the microfiber extrudate has a diameter of less than about 110 micrometers. 
     
     
         3 . The microfiber extrusion of  claim 1 , wherein the exogenously excitable material is arranged in at least one discrete domain. 
     
     
         4 . The microfiber extrudate of  claim 3 , wherein the microfiber extrudate is a size and geometry substantially similar to a red blood cell or white blood cell. 
     
     
         5 . The microfiber extrusion of  claim 1 , wherein the active load is arranged in at least one discrete domain. 
     
     
         6 . The microfiber extrudate of  claim 1 , wherein the microfiber extrudate has an elongate structure. 
     
     
         7 . The microfiber extrudate of  claim 1 , wherein the microfiber extrudate has a transverse thickness of less than about 12 micrometers. 
     
     
         8 . The microfiber extrudate of  claim 1 , wherein the exogenously excitable material is configured to be excited by an exogenous stimulus selected from the group of stimuli consisting of radiofrequency excitation, microwave excitation, terahertz excitation, mid infrared excitation, near infrared excitation, visible excitation, ultraviolet excitation, x-irradiation excitation, magnetic excitation, electron beam irradiation excitation, and combinations thereof. 
     
     
         9 . The microfiber extrudate of  claim 1 , wherein the exogenously excitable material is a radiosensitive chemotherapeutic material and the active load is a non-radiosensitive chemotherapeutic agent. 
     
     
         10 . The microfiber extrudate of  claim 1 , wherein the active load comprises an antibody. 
     
     
         11 . The microfiber extrudate of  claim 1 , wherein the active load comprises an anti-VEGH. 
     
     
         12 . The microfiber extrudate of  claim 1 , wherein the exogenously excitable material is a radiosensitive chemotherapeutic agent. 
     
     
         13 . The microfiber extrudate of  claim 1 , wherein the active load comprises an active pharmaceutical ingredient. 
     
     
         14 . The microfiber extrudate of  claim 1 , wherein the active load is a non-radiosensitive chemotherapeutic agent. 
     
     
         15 . The microfiber extrudate of  claim 1 , wherein the bio-compatible polymer matrix comprises a polymer selected from the group consisting of poly(FAD-SA), poly(CCP-SA), poly(FA-SA), poly(EAD-SA), poly glycolide, poly lactic acid, copolymers thereof, and combinations thereof. 
     
     
         16 . The microfiber extrudate of  claim 1 , wherein the bio-compatible polymer matrix comprises a polyglycolide copolymer. 
     
     
         17 . The microfiber extrudate of  claim 1 , wherein the microfiber extrudate is arranged and disposed for transforming its shape. 
     
     
         18 . A microfiber extrudate comprising
 a bio-compatible polymer matrix forming a body of the microfiber extrudate; and   an exogenously excitable material arranged in at least one discrete domain within the body.   
     
     
         19 . The exogenously excitable domain of  claim 18 , wherein the exogenously excitable material is a superparamagnetic iron oxide non-particle. 
     
     
         20 . A microfiber extrudate comprising
 a bio-compatible polymer matrix forming a body of the microfiber extrudate; and   an active pharmaceutical agreement or an antibody arranged as at least one discrete domain within the body.   
     
     
         21 . A microfiber extrudate delivery process comprising:
 identifying a region for treatment;   medically administering a microfiber extrudate to the region for treatment, the microfiber extrudate comprising:
 a bio-compatible polymer matrix forming a body of the microfiber extrudate; 
 an exogenously excitable material arranged within the body; and 
 an active load arranged as a discrete domain within the body; and thereafter 
   applying exogenous stimulus to the region for treatment, thereby releasing the active load into the region for treatment.   
     
     
         22 . A microfiber extrudate comprising:
 a bio-compatible polymer matrix forming a body of the microfiber extrudate, the bio-compatible polymer matrix comprising a polymer selected from the group consisting of poly(FAD-SA), poly(CCP-SA), poly(FA-SA), poly(EAD-SA), poly glycolide, poly lactic acid, copolymers thereof, and combinations thereof;   an exogenously excitable material arranged in at least one discrete domain within the body, the exogenously excitable material configured to be excited by an exogenous stimulus selected from the group of stimuli consisting of radiofrequency excitation, microwave excitation, terahertz excitation, mid infrared excitation, near infrared excitation, visible excitation, ultraviolet excitation, x-irradiation excitation, magnetic excitation, electron beam irradiation excitation, and combinations thereof; and   an active load arranged in at least one discrete domain within the body, the active load having therapeutic properties.   
     
     
         23 . The microfiber extrudate of  claim 22 , wherein the exogenously excitable material comprises a radiosensitive chemotherapeutic agent, the active load comprises a non-radiosensitive chemotherapeutic agent, and the active load comprises an antibody. 
     
     
         24 . The microfiber extrudate of  claim 22 , wherein the active load comprises acetaminophen. 
     
     
         25 . The microfiber extrudate of  claim 22 , wherein the microfiber extrudate is arranged and disposed for transforming its shape.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.